Sector News

Clinical trial firms tap social media ‘influencers’ for virtual trial recruitment drive

March 20, 2021
Life sciences

As the hype around so-called siteless trials continues unabated, two trial tech firms are joining forces to tap social media influencers to help push more patients into studies.

The pair: decentralized clinical research company Thread and trial recruitment firm CureClick. They say their new pact will allow sponsors and contract research organizations to “access the power of patient activist-driven crowdsourcing to improve recruitment” in virtual trials.

They will do this by tapping as yet unnamed social media influencers by combining Thread’s platform with CureClick’s network of more than 100,000 so-called patient activists and advocates.

This will presumably be for a younger generation of patients; the pair did not say what sort of trials they were planning to tackle. But it provides a new way of tapping into the tough trial recruitment area, which has always proven a major barrier in drug development.

“We are excited for this partnership to advance recruitment for DCTs,” said Fabio Gratton, CEO of CureClick. “THREAD is the leading DCT provider, and by joining forces, we can better fulfill our mission to help life science organizations recruit patients faster while ensuring they have the best possible experience at every step.”

“We have great admiration for CureClick’s ability to drive exceptional recruitment outcomes through its ambassador network of patient activists,” added John Reites, CEO of Thread. “Having worked successfully with CureClick on several studies in the past, we are excited to deepen our collective impact on DCTs through a more formal partnership.”

by Ben Adams

Source: fiercebiotech.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend